Related Experiment Video

Updated: Nov 2, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.6K

The role of tazemetostat in relapsed/refractory follicular lymphoma

Gottfried von Keudell1, Gilles Salles2

  • 1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Therapeutic Advances in Hematology
|June 9, 2021
PubMed

Insights

Tazemetostat offers a new oral treatment for relapsed follicular lymphoma (FL), particularly for patients with EZH2 mutations or limited options. This targeted therapy addresses disease progression after initial treatments.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Follicular lymphoma (FL) treatment advances have been significant, yet many patients face disease progression.
  • Relapsed FL necessitates novel therapeutic strategies due to shortened treatment-free intervals.
  • Enhancer of zester homolog 2 (EZH2) mutations occur in approximately 25% of FL cases.

Purpose of the Study:

  • To review the development and approval of tazemetostat for relapsed FL.
  • To summarize key clinical data supporting tazemetostat's efficacy.
  • To highlight tazemetostat as a novel treatment option for specific FL patient populations.

Main Methods:

  • Review of preclinical and clinical trial data for tazemetostat.
  • Analysis of patient populations with relapsed FL and EZH2 mutations.
  • Evaluation of regulatory submission data for drug approval.

Main Results:

  • Tazemetostat demonstrated efficacy in patients with relapsed FL, including those with EZH2 mutations.
  • Approval was granted for relapsed FL patients with EZH2 mutations after two prior therapies.
  • It is also indicated for patients with no other therapeutic options, irrespective of mutation status.

Conclusions:

  • Tazemetostat represents a significant advancement in relapsed FL treatment.
  • Its approval provides a crucial new option for patients with limited therapeutic choices.
  • Targeting EZH2 offers a promising avenue for follicular lymphoma management.
Keywords:
Enhancer of zester homologue 2 (EZH2)clinical trialepigeneticfollicular lymphomatargeted therapy

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.6K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
791
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
47